科濟藥業-B(02171.HK):舒瑞基奧侖賽注射液用於胰腺癌輔助治療試驗結果摘要已獲2025年ESMO年會接受進行壁報展示
格隆匯7月22日丨科濟藥業-B(02171.HK)宣佈,舒瑞基奧侖賽注射液(產品編號:CT041,一種靶向Claudin18.2的自體CAR-T細胞治療候選產品)在中國開展的針對胰腺癌(PC) 輔助治療的Ib期註冊臨牀試驗(CT041-ST-05,NCT05911217)初步結果已被2025 年歐洲腫瘤內科學會(ESMO)年會接受進行壁報展示。摘要將於2025年10月13日(星期一)歐洲中部夏令時間(CEST)00:05於ESMO官網公佈。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.